Previous 10 | Next 10 |
Artelo Biosciences (ARTL) traded 3.4% higher premarket after exercising a portion of its warrants from its October 2020 financing.Existing investors agreed to exercise warrants for net proceeds of ~$3M."The proceeds from the exercise of these warrants strengthen our balanc...
LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a p...
Gainers: Cassava Sciences (SAVA) +126%.Ocugen (OCGN) +75%.American Resources (AREC) +51%.Lizhi (LIZI) +46%.Aeterna Zentaris (AEZS) +35%.Moleculin Biotech (MBRX) +35%.Holicity (HOL) +35%.Prothena (PRTA) +32%.TETRA Technologies (TTI) +32%.Artelo Biosciences (ARTL) +29%.Losers: Ga...
Gainers: Ocugen OCGN +76%, Cassava Sciences SAVA +65%, Moleculin Biotech MBRX +47%, Artelo Biosciences (ARTL) +28%, Atossa Therapeutics (ATOS) +20%.Losers: Immunovant IMVT -39%, Dynavax Technologies (DVAX) -19%, Retractable Technolog...
LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 8...
Artelo Biosciences (ARTL) +78%.Moleculin Biotech (MBRX) +49% on announcing 100% survival achieved in Osteosarcoma Lung Metastases Animal Model.DURECT (DRRX) +42% after FDA approval for Posimir.Holicity (HOLUU) +38% on plan to take rocket maker Astra public.Tiziana Life Sciences...
LA JOLLA, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be pre...
Artelo Biosciences (ARTL): Q1 GAAP EPS of -$0.14 misses by $0.04.Cash and cash equivalents of ~$7.39M.Shares are up 1% PM.Press Release For further details see: Artelo Biosciences EPS misses by $0.04
Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK Awarded Mitacs Accelerate Grant LA JOLLA, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a c...
Lion Group Holding (LGHL) +142%.SCWorx (WORX) +55%.Future FinTech Group (FTFT) +41%.Optical Cable Corporation (OCC) +29%.ZW Data Action Technologies (CNET) +29%.Jaguar Health (JAGX) +25%.Merus N.V. (MRUS) +24% after FDA grants Fast Track designation to it's Zenocutuzumab.Ideanomics ...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...